- NVP-TAE 226
-
- $41.00 / 1mg
-
2025-04-29
- CAS:761437-28-9
- Min. Order:
- Purity: 98.07%
- Supply Ability: 10g
- TAE226 (NVP-TAE226)
-
- $1.00 / 1KG
-
2019-09-06
- CAS:761437-28-9
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 20kg
|
| TAE226 (NVP-TAE226) Basic information |
Product Name: | TAE226 (NVP-TAE226) | Synonyms: | NVP-TAE 226;TAE226;TAE226 (NVP-TAE226);2-((5-Chloro-2-((2-methoxy-4-morpholinophenyl)-amino)pyrimidin-4-yl)amino)-N-methylbenzamide;Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-;NVP-TAE 226 2-[[5-Chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methylbenzamide;2-[[5-Chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methylbenzamide;TAE226 (NVP-TAE226) USP/EP/BP | CAS: | 761437-28-9 | MF: | C23H25ClN6O3 | MW: | 468.94 | EINECS: | | Product Categories: | Inhibitors | Mol File: | 761437-28-9.mol |  |
| TAE226 (NVP-TAE226) Chemical Properties |
density | 1.349 | storage temp. | Store at -20°C | solubility | ≥23.45 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | form | solid | pka | 14.57±0.46(Predicted) | color | White to khaki |
| TAE226 (NVP-TAE226) Usage And Synthesis |
Description | NVP-TAE226 is an inhibitor of focal adhesion kinase (FAK; IC50 = 5.5 nM) and the related proline-rich tyrosine kinase 2-β (PYK2β; IC50 = 5 nM). It can also inhibit the insulin-like growth factor 1 receptor (IC50 = 0.16 μM) as well as the activity of its downstream target genes such as MAPK and Akt. NVP-TAE226 has been shown to inhibit glioma and ovarian tumor growth in in vivo tumor models. | Uses | NVP-TAE 226 is FAK and IGF-IR inhibitor. It can be used in biological study and therapeutic use of TAE226, a bis-?anilino pyrimidine compound, inhibits the egfr-?mutant kinase including T790M mutant to show anti-?tumor effect on EGFR-?mutant non-?small cell lung cancer cells. | Definition | ChEBI: 2-[[5-chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl]amino]-N-methylbenzamide is a member of morpholines. | in vivo | Treatment with NVP-TAE 226 (TAE226) at 50 or 75 mg/kg extends the median survival of U87 xenograft animals by 6 and 7 days, respectively (P=0.084 and P=0.042, respectively, compared with vehicle-treated animals). However, NVP-TAE 226 treatment of LN229-engrafted animals significantly prolongs their median survival by 19 days (P<0.004 for both dosages, compared with vehicle-treated animals)[1]. | target | PYK2 | references | [1]. liu, t.j., et al., inhibition of both focal adhesion kinase and insulin-like growth factor-i receptor kinase suppresses glioma proliferation in vitro and in vivo. mol cancer ther, 2007. 6(4): p. 1357-67. [2]. plaza-menacho, i., et al., focal adhesion kinase (fak) binds ret kinase via its ferm domain, priming a direct and reciprocal ret-fak transactivation mechanism. j biol chem, 2011. 286(19): p. 17292-302. |
| TAE226 (NVP-TAE226) Preparation Products And Raw materials |
|